Avidicure’s CEO Arthur Lahr sat down with the GlobalData Insights Investigative News team to talk about its CRO selection for the Phase I study of solid tumor mAb AVC-S-101, as well as other partnership initiatives for 2026 and 2027.

Read the full report here